These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 19033477)

  • 1. Pulsating back pain associated with tumor necrosis factor-alpha blockade.
    Rozin AP; Braun-Moscovici Y; Balbir-Gurman A
    Ann Pharmacother; 2008 Dec; 42(12):1912-3. PubMed ID: 19033477
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis.
    Favalli EG; Arreghini M; Arnoldi C; Panni B; Marchesoni A; Tosi S; Pontikaki I
    Arthritis Rheum; 2004 Apr; 51(2):301-2. PubMed ID: 15077278
    [No Abstract]   [Full Text] [Related]  

  • 3. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
    Guillevin L; Mouthon L
    J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
    [No Abstract]   [Full Text] [Related]  

  • 4. Perforating folliculitis associated with tumour necrosis factor-alpha inhibitors administered for rheumatoid arthritis.
    Gilaberte Y; Coscojuela C; Vázquez C; Roselló R; Vera J
    Br J Dermatol; 2007 Feb; 156(2):368-71. PubMed ID: 17223880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: two cases.
    Dereure O; Guillot B; Jorgensen C; Cohen JD; Combes B; Guilhou JJ
    Br J Dermatol; 2004 Aug; 151(2):506-7. PubMed ID: 15327565
    [No Abstract]   [Full Text] [Related]  

  • 6. Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs.
    Curtis JR; Martin C; Saag KG; Patkar NM; Kramer J; Shatin D; Allison J; Braun MM
    Arthritis Rheum; 2007 Mar; 57(2):343-6. PubMed ID: 17330283
    [No Abstract]   [Full Text] [Related]  

  • 7. Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases.
    Lourari S; Prey S; Livideanu C; Jamard B; Lamant L; Cantagrel A; Paul C
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):967-8. PubMed ID: 19192017
    [No Abstract]   [Full Text] [Related]  

  • 8. Relapsing polychondritis: a new adverse event secondary to the use of tumour necrosis factor antagonists?
    Hernández MV; Ruiz-Esquide V; Gómez-Caballero ME; Gómez-Puerta JA; Cañete JD; Sanmartí R
    Rheumatology (Oxford); 2011 Aug; 50(8):1523-5. PubMed ID: 21593064
    [No Abstract]   [Full Text] [Related]  

  • 9. Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers.
    Richez C; Blanco P; Lagueny A; Schaeverbeke T; Dehais J
    Neurology; 2005 Apr; 64(8):1468-70. PubMed ID: 15851749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can tumor necrosis factor alpha blockade predispose to severe babesiosis?
    Taiwo B; Lee C; Venkat D; Tambar S; Sutton SH
    Arthritis Rheum; 2007 Feb; 57(1):179-81. PubMed ID: 17266091
    [No Abstract]   [Full Text] [Related]  

  • 11. Prescribing antitumor necrosis factor drugs to patients with heart failure.
    Ziegelstein RC
    Arch Intern Med; 2005 Jan; 165(1):118-9. PubMed ID: 15642887
    [No Abstract]   [Full Text] [Related]  

  • 12. Cutaneous pseudolymphoma associated with a TNF-alpha inhibitor treatment: etanercept.
    Guis S; Schiano de Colella JM; Bonnet N; Andrac-Meyer L; Balandraud N; Mattei JP; Franck B; Roudier C; Roudier J; Berbis P
    Eur J Dermatol; 2008; 18(4):474-6. PubMed ID: 18573737
    [No Abstract]   [Full Text] [Related]  

  • 13. Unstable diabetes in a patient receiving anti-TNF-alpha for rheumatoid arthritis.
    Boulton JG; Bourne JT
    Rheumatology (Oxford); 2007 Jan; 46(1):178-9. PubMed ID: 16998233
    [No Abstract]   [Full Text] [Related]  

  • 14. Psoriasis induced by anti-tumor necrosis factor therapy: a class effect?
    Richette P; Viguier M; Bachelez H; Bardin T
    J Rheumatol; 2007 Feb; 34(2):438-9. PubMed ID: 17304662
    [No Abstract]   [Full Text] [Related]  

  • 15. Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis.
    Day R
    Lancet; 2002 Feb; 359(9306):540-1. PubMed ID: 11867103
    [No Abstract]   [Full Text] [Related]  

  • 16. Why does tumor necrosis factor targeted therapy reactivate tuberculosis?
    Ehlers S
    J Rheumatol Suppl; 2005 Mar; 74():35-9. PubMed ID: 15742463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-tumor necrosis factor-alpha-induced psoriasis.
    Sari I; Akar S; Birlik M; Sis B; Onen F; Akkoc N
    J Rheumatol; 2006 Jul; 33(7):1411-4. PubMed ID: 16821276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Unnecessary to scare the patients].
    Hansen B; Book C
    Lakartidningen; 2006 Jan 11-17; 103(1-2):63. PubMed ID: 16465854
    [No Abstract]   [Full Text] [Related]  

  • 20. Psoriasiform and pustular eruption induced by etanercept and infliximab.
    Kuhara T; Watanabe D; Iwahori Y; Tamada Y; Yamamura M; Matsumoto Y
    Eur J Dermatol; 2009; 19(4):388-9. PubMed ID: 19467963
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.